Ardelyx to Participate at the 2024 Jefferies Global Healthcare Conference

Rhea-AI Summary

Ardelyx, a biopharmaceutical company (Nasdaq: ARDX), will participate in the 2024 Jefferies Global Healthcare Conference. Michael Raab, President and CEO, alongside Justin Renz, Chief Financial and Operations Officer, will engage in a fireside chat on June 5, 2024, at 10:00 A.M. Eastern Time in New York City. The event will be accessible via live webcast on the Ardelyx website, with a replay available for 30 days after the event.

Positive

• Participation in the prestigious 2024 Jefferies Global Healthcare Conference can enhance Ardelyx's visibility and credibility in the biopharmaceutical industry.
• Engagement by high-ranking officials like the CEO and CFO at such events indicates strong leadership involvement and transparency.
• The availability of a live webcast and a 30-day replay offers extensive access for investors and stakeholders, promoting transparency and engagement.

Negative

• No specific financial or clinical updates were provided in this announcement, which might be seen as a lack of new substantial progress or news.
• The stock performance might not see immediate or significant impact solely based on participation in an industry conference.

WALTHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Michael Raab, President and CEO, and Justin Renz, chief financial and operations officer, will participate in a fireside chat at the 2024 Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 10:00 A.M. Eastern Time in New York City.

To access the live webcast of the panel presentation please visit the Events and Presentations page within the Ardelyx website at https://ir.ardelyx.com/events-and-presentations. A replay of the panel presentation will be available on the Ardelyx website for 30 days following the event.

About Ardelyx, Inc.
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA^® (tenapanor) and XPHOZAH^® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL^® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.

Investor and Media Contacts:
Caitlin Lowie
clowie@ardelyx.com

FAQ

When will Ardelyx participate in the Jefferies Global Healthcare Conference?

Ardelyx will participate on June 5, 2024, at 10:00 A.M. Eastern Time.

Who from Ardelyx will be participating in the 2024 Jefferies Global Healthcare Conference?

Michael Raab, President and CEO, and Justin Renz, Chief Financial and Operations Officer, will be participating.

How can I access the live webcast of Ardelyx's presentation at the 2024 Jefferies Global Healthcare Conference?

You can access the live webcast on the Events and Presentations page of the Ardelyx website.

Will a replay of Ardelyx's presentation at the 2024 Jefferies Global Healthcare Conference be available?

Yes, a replay will be available on the Ardelyx website for 30 days following the event.

What is the stock symbol for Ardelyx?

The stock symbol for Ardelyx is ARDX.